Neumora Therapeutics is trading 5.57% higher at $0.45, with no clear company-specific catalyst identified for the October 16 move.
- It closed October 15 at $0.43, up 20.45%.
- A market listing showed no company headlines dated October 16.
- Biotech was lower, and earlier analyst rating changes and pipeline setbacks are not evidence of a new catalyst; the reason for the live move remains unclear.